p. 1421−1430
2090-7125
Vol.70/No.9
p. 1431−1439
2090-7125
Vol.70/No.9
p. 1440−1444
2090-7125
Vol.70/No.9
A transverse mutation. The patient achieved a modest response to treatment with phenytoin, carbamazepine or acetazolamide. His condition remained stable with minimal weakness and muscle hypertrophy.
Conclusions: myotonia congenita is a rare genetic disorder of muscle relaxation. The diagnosis is made based on clinical features and is confirmed by sequencing CLCN1 gene. Response to treatment is variable. Recommended medications included mexiletine, phenytoin, carbamazepine and acetazolamide among others.]]>
p. 1445−1447
2090-7125
Vol.70/No.9
p. 1448−1454
2090-7125
Vol.70/No.9
p. 1455−1463
2090-7125
Vol.70/No.9
p. 1464−1467
2090-7125
Vol.70/No.9
p. 1468−1470
2090-7125
Vol.70/No.9
p. 1471−1474
2090-7125
Vol.70/No.9
p. 1475−1479
2090-7125
Vol.70/No.9
p. 1480−1483
2090-7125
Vol.70/No.9
p. 1484−1493
2090-7125
Vol.70/No.9
p. 1494−1507
2090-7125
Vol.70/No.9
p. 1508−1510
2090-7125
Vol.70/No.9
p. 1511−1517
2090-7125
Vol.70/No.9
p. 1518−1528
2090-7125
Vol.70/No.9
p. 1529−1538
2090-7125
Vol.70/No.9
p. 1539−1543
2090-7125
Vol.70/No.9
p. 1544−1551
2090-7125
Vol.70/No.9
p. 1552−1561
2090-7125
Vol.70/No.9
3.5). There was an association between IR and NASH (p=0.011), IR and obesity (p=0.031), IR and MS (p=0.007), and MS and steatosis on medical ultrasound (USG) (p=0.012).
Conclusion: The results indicated that the most frequent risk factors were MS and its variables: increased waist circumference, dyslipidemia and HBP. This highlights the significance of metabolic control in non-alcoholic fatty liver disease and confirms its role as the hepatic component of metabolic syndrome.]]>
p. 1552−1567
2090-7125
Vol.70/No.9
p. 1568−1571
2090-7125
Vol.70/No.9
25 cigarettes/day compared with never smokers. The risk estimate for former smokers was similar to never smokers.
Conclusions: Tobacco smoking is an important independent risk factor for acute myocardial infarction in young adults, with similar strength of association for both genders.]]>
p. 1572−1575
2090-7125
Vol.70/No.9
p. 1676−1681
2090-7125
Vol.70/No.9
p. 1582−1585
2090-7125
Vol.70/No.9
p. 1686−1694
2090-7125
Vol.70/No.9
p. 1695−1702
2090-7125
Vol.70/No.9
p. 1703−1709
2090-7125
Vol.70/No.9
p. 1710−1713
2090-7125
Vol.70/No.9
p. 1714−1718
2090-7125
Vol.70/No.9